Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety
| Autor: | Robert Glazer, David A. Calhoun, Nora Crikelair, Joseph Yen |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Urology Tetrazoles Blood Pressure law.invention Hydrochlorothiazide Double-Blind Method Randomized controlled trial law Internal medicine Triple combination Humans Medicine Pharmacology (medical) Amlodipine Antihypertensive Agents business.industry Valine General Medicine Rheumatology Drug Combinations Blood pressure Valsartan Hypertension Female Amlodipine-Valsartan business medicine.drug |
| Zdroj: | Advances in Therapy. 26:1012-1023 |
| ISSN: | 1865-8652 0741-238X |
| DOI: | 10.1007/s12325-009-0077-7 |
| Popis: | An 8-week trial of amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCTZ) for moderate or severe hypertension demonstrated more-pronounced blood pressure (BP)-lowering effects compared with dual-component therapies. To elucidate the effects of time and baseline BP on the observed responses, exploratory analyses were performed.Patients aged 18-85 years with mean sitting systolic BP (MSSBP) 145 to200 mmHg and mean sitting diastolic BP (MSDBP) 100 to120 mmHg were randomized to Aml 10 mg/Val 320 mg/HCTZ 25 mg; Val 320 mg/HCTZ 25 mg; Aml 10 mg/Val 320 mg; or Aml 10 mg/HCTZ 25 mg. During the first 2 weeks, regimens were force-titrated in two stages.All least-square mean reductions in MSSBP and MSDBP (baseline to Week 3 and end of study) were significantly greater with triple therapy than with each dual therapy in the overall population and the severe systolic subgroup (baseline MSSBPor =180 mmHg; except vs. Aml 10 mg/Val 320 mg at Week 3). At Week 3, more patients on triple therapy achieved MSSBP reductions ofor =-60,or =-50,or =-40,or =-30, andor =-20 mmHg (2.5%, 9.7%, 23.2%, 46.9% and 74.5%, respectively) than those on dual therapy (1.1%-2%, 5.6%-5.9%, 14.5%-16.7%, 33.5%-39.1%, and 58.8%-65.5%, respectively); this was also true at study endpoint. End-of-study MSSBP reductions were greater in triple-therapy recipients who had higher (vs. lower) baseline MSSBPs. LSM reductions ranged from -27.2 mmHg for baseline MSSBP 145 to150 mmHg, toor =49.6 mmHg for baseline MSSBPor =180 mmHg. All treatments were well tolerated regardless of baseline MSSBP.Aml 10 mg/Val 320 mg/HCTZ 25 mg triple therapy is highly effective in reducing BP compared with dual components early in therapy, and systolic BP-lowering effects were proportionate to hypertension severity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink